Highlights Cosmo Pharmaceuticals N.V.

Equities

COPN

NL0011832936

Market Closed - Swiss Exchange Other stock markets 16:30:41 31/05/2024 BST			5-day change	1st Jan Change
70.8 ^CHF	+0.43%		-0.98%	+39.10%

04-26	Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024	CI
04-25	Cosmo Pharmaceuticals Names New CEO, Chairman	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cosmo Pharmaceuticals N.V. Proposes Dividend Payment for 2024	03-20	CI
Cosmo Pharmaceuticals N.V. Provides Earnings Guidance for the Year 2024 and Revenue Guidance for 2025	03-20	CI
Cosmo Pharmaceuticals' FY23 Profit, Revenue Drops	03-20	MT
Cosmo Pharmaceuticals N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	03-19	CI
Medtronic Expands Partnership With Cosmo Pharmaceuticals Unit	12-11	MT
Cosmo Pharmaceuticals, Medtronic to Boost AI Focus in Expanded Partnership	12-11	MT
Cosmo Pharmaceuticals Redeems EUR175 Million of Bonds due 2023	12-06	MT
Global markets live: Nvidia, Chevron, FedEx, Roche, PepsiCo...	10/10/23
Cosmo Pharmaceuticals Files Marketing Authorization Application in Europe for Topical Acne Treatment	10/10/23	MT
Cosmo Pharmaceuticals Licenses Acne Treatment Winlevi to Hikma in Middle East, North Africa	02/10/23	MT
Cosmo Pharmaceuticals Signs Distribution, Licensing Deals with Glenmark for Acne Cream in Europe, South Africa	27/09/23	MT
Cosmo Pharmaceuticals N.V. and Glenmark Specialty S.A. Announce the Signing of Distribution and License Agreements for Winlevi® in Europe and South Africa	27/09/23	CI
Cosmo Pharmaceuticals Signs License Deal With Adalvo for Rifamycin	04/09/23	MT
Cosmo Pharmaceuticals Cancels Dr. Falk Pharma's EU License for Travelers' Diarrhea Drug	04/09/23	MT
Cosmo Pharmaceuticals N.V. Reiterates Earnings Guidance for the Year 2023	26/07/23	CI
Cosmo Pharmaceuticals N.V. Reports Earnings Results for the Half Year Ended June 30, 2023	26/07/23	CI
Cosmo Pharmaceuticals Posts Lower H1 Post-tax Profit; Revenue Rises	26/07/23	MT
Cosmo Pharmaceuticals N.V. Announces the Beginning of the Phase III Trials in Men for the Treatment of Androgenetic Alopecia	29/06/23	CI
Cosmo Pharmaceuticals Wins Japanese Nod For Ulcerative Colitis Drug	28/06/23	MT
Cosmo Pharmaceuticals Licenses Topical Acne Medication to Hyundai Pharmaceuticals in South Korea	22/06/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cosmo Pharmaceuticals N.V.

Equities

COPN

NL0011832936

Highlights

Filters